Supportive care of patients diagnosed with high grade glioma and their carers in Australia.

Halkett, GKB; Berg, MN; Daudu, D; Dhillon, HM; Koh, E-S; Ownsworth, T; Lobb, E; Phillips, J; Langbecker, D; Agar, M; Hovey, E; Moorin, R; Nowak, AK

Supportive care of patients diagnosed with high grade glioma and their carers in Australia.

Halkett, GKB Berg, MN Daudu, D Dhillon, HM Koh, E-S Ownsworth, T Lobb, E Phillips, J

Langbecker, D Agar, M

Hovey, E Moorin, R Nowak, AK

Permalink

Publisher:: Springer
Publication Type:: Journal Article
Citation:: Journal of Neuro-Oncology, 2022, 157, (3), pp. 475-485
Issue Date:: 2022-05

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Supportive care of patients diagnosed with high grade glioma and their carers in Australia.pdfAdobe PDF (733.31 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Halkett, GKB
dc.contributor.author	Berg, MN
dc.contributor.author	Daudu, D
dc.contributor.author	Dhillon, HM
dc.contributor.author	Koh, E-S
dc.contributor.author	Ownsworth, T
dc.contributor.author	Lobb, E
dc.contributor.author	Phillips, J https://orcid.org/0000-0002-3691-8230
dc.contributor.author	Langbecker, D
dc.contributor.author	Agar, M https://orcid.org/0000-0002-6756-6119
dc.contributor.author	Hovey, E
dc.contributor.author	Moorin, R
dc.contributor.author	Nowak, AK
dc.date.accessioned	2022-09-30T03:57:03Z
dc.date.available	2022-03-18
dc.date.available	2022-09-30T03:57:03Z
dc.date.issued	2022-05
dc.identifier.citation	Journal of Neuro-Oncology, 2022, 157, (3), pp. 475-485
dc.identifier.issn	0167-594X
dc.identifier.issn	1573-7373
dc.identifier.uri	http://hdl.handle.net/10453/162192
dc.description.abstract	PURPOSE: This study aimed to: determine the supportive care available for Australian patients with High Grade Glioma (HGG) and their carers; identify service gaps; and inform changes needed to implement guidelines and Optimal Care Pathways. METHODS: This cross-sectional online survey recruited multidisciplinary health professionals (HPs) who were members of the Cooperative Trials Group for Neuro-Oncology involved in management of patients diagnosed with HGG in Australian hospitals. Descriptive statistics were calculated. Fisher's exact test was used to explore differences between groups. RESULTS: 42 complete responses were received. A majority of MDT meetings were attended by a: neurosurgeon, radiation oncologist, medical oncologist, radiologist, and care coordinator. Less than 10% reported attendance by a palliative care nurse; physiotherapist; neuropsychologist; or speech therapist. Most could access referral pathways to a cancer care coordinator (76%), neuropsychologist (78%), radiation oncology nurse (77%), or psycho-oncologist (73%), palliative care (93-100%) and mental health professionals (60-85%). However, few routinely referred to an exercise physiologist (10%), rehabilitation physician (22%), dietitian (22%) or speech therapist (28%). Similarly, routine referrals to specialist mental health services were not standard practice. Nearly all HPs (94%) reported HGG patients were advised to present to their GP for pre-existing conditions/comorbidities; however, most HPs took responsibility (≤ 36% referred to GP) for social issues, mental health, symptoms, cancer complications, and treatment side-effects. CONCLUSIONS: While certain services are accessible to HGG patients nationally, improvements are needed. Psychosocial support, specialist allied health, and primary care providers are not yet routinely integrated into the care of HGG patients and their carers despite these services being considered essential in clinical practice guidelines and optimal care pathways.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Springer
dc.relation.ispartof	Journal of Neuro-Oncology
dc.relation.isbasedon	10.1007/s11060-022-03991-z
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1109 Neurosciences, 1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Australia
dc.subject.mesh	Caregivers
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Glioma
dc.subject.mesh	Humans
dc.subject.mesh	Palliative Care
dc.subject.mesh	Australia
dc.subject.mesh	Caregivers
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Glioma
dc.subject.mesh	Humans
dc.subject.mesh	Palliative Care
dc.subject.mesh	Humans
dc.subject.mesh	Glioma
dc.subject.mesh	Palliative Care
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Caregivers
dc.subject.mesh	Australia
dc.title	Supportive care of patients diagnosed with high grade glioma and their carers in Australia.
dc.type	Journal Article
utslib.citation.volume	157
utslib.location.activity	United States
utslib.for	1109 Neurosciences
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2022-09-30T03:57:00Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	157
utslib.citation.issue	3

Abstract:

PURPOSE: This study aimed to: determine the supportive care available for Australian patients with High Grade Glioma (HGG) and their carers; identify service gaps; and inform changes needed to implement guidelines and Optimal Care Pathways. METHODS: This cross-sectional online survey recruited multidisciplinary health professionals (HPs) who were members of the Cooperative Trials Group for Neuro-Oncology involved in management of patients diagnosed with HGG in Australian hospitals. Descriptive statistics were calculated. Fisher's exact test was used to explore differences between groups. RESULTS: 42 complete responses were received. A majority of MDT meetings were attended by a: neurosurgeon, radiation oncologist, medical oncologist, radiologist, and care coordinator. Less than 10% reported attendance by a palliative care nurse; physiotherapist; neuropsychologist; or speech therapist. Most could access referral pathways to a cancer care coordinator (76%), neuropsychologist (78%), radiation oncology nurse (77%), or psycho-oncologist (73%), palliative care (93-100%) and mental health professionals (60-85%). However, few routinely referred to an exercise physiologist (10%), rehabilitation physician (22%), dietitian (22%) or speech therapist (28%). Similarly, routine referrals to specialist mental health services were not standard practice. Nearly all HPs (94%) reported HGG patients were advised to present to their GP for pre-existing conditions/comorbidities; however, most HPs took responsibility (≤ 36% referred to GP) for social issues, mental health, symptoms, cancer complications, and treatment side-effects. CONCLUSIONS: While certain services are accessible to HGG patients nationally, improvements are needed. Psychosocial support, specialist allied health, and primary care providers are not yet routinely integrated into the care of HGG patients and their carers despite these services being considered essential in clinical practice guidelines and optimal care pathways.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/162192